RADNOR, Pa., April 23, 2026 /PRNewswire/ — Avantor, Inc. (NYSE: AVTR), a leading global provider of…
Category: News
Accord Specialty Pharmacy Named Finalist in MMIT’s 11th Annual Retail Specialty Pharmacy Patient Choice Awards
ORLANDO, Fla., April 23, 2026 /PRNewswire/ — Accord Specialty Pharmacy, an independent specialty pharmacy serving patients…
Community Access, Mega Group and Public Officials Celebrate Groundbreaking of 213-Unit Affordable and Supportive Housing Development in the Bronx
The $162 million project will feature a health center operated by Community Healthcare Network BRONX, N.Y.,…
The Inner Circle acknowledges Patrick Tamim as a 2026 Professional of the Year
PANAMA CITY, Fla., April 23, 2026 /PRNewswire/ –Prominently featured in The Inner Circle, Patrick Tamim is…
ONCare Alliance Announces Addition of Premier Cancer Care & Infusion Center to Its Network
WASHINGTON, April 23, 2026 /PRNewswire/ — ONCare Alliance, the leading network dedicated to empowering independent oncology…
Fapon Biopharma Presents at AACR Annual Meeting 2026, Showcasing Core Technology Platforms and Advancing Pipeline
SAN DIEGO, April 20, 2026 /PRNewswire/ — Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies…
Following Pivotal Trial, FDA Set to Review First-of-a-Kind VR Autism Therapy
WASHINGTON, April 20, 2026 /PRNewswire/ –Floreo, a developer of virtual reality (VR)-based therapeutic technologies, today announced…
Top 5 Gundry MD Total Restore Reviews: Will It Improve Your Gut Health?
Reviews Highlight Powerful Gut Health Support for Digestion, Energy & Overall Wellness LOS ANGELES, April 20,…
"The Best Protein Supplement We’ve Ever Used" Power Life High Impact Protein Receives 92% Positive Customer Reviews Nationwide
Power Life High Impact Protein Whey and Plant-Based Blends Feature HMB, Vitamin D3, and Digestive Enzymes…
U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Submission based on statistically significant event-free and overall survival data from the Phase 3 EV-304 trial…